



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Number : 10/642,272 Confirmation No.: 3248  
Applicant : Fumiyuki HATTORI, et al.  
Filed : August 18, 2003  
Title : THERAPEUTIC METHODS AND AGENTS FOR DISEASES  
ASSOCIATED WITH DECREASED EXPRESSION OF AOP-1  
GENE OR AOP-1  
TC/Art Unit : 1632  
Examiner: : Marcia Noble STEPHENS, Ph.D.  
Docket No. : 58777.000012  
Customer No. : **21967**

**Mail Stop Box Sequence**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Substitute Sequence Listing and Statement under 37 C.F.R. §§ 1.821 and 1.825**

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.821 and 1.825, Applicants submit herewith a substitute paper copy of "Sequence Listing," totaling fourteen (14) pages. Applicants submit herewith a substitute computer readable copy of the "Sequence Listing" on a CD-ROM in ASCII format as required by 37 C.F.R. §§ 1.821(e) and 1.825(a).

In accordance with the provisions of 37 C.F.R. § 1.821(f), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the "Sequence Listing" submitted herewith are identical.

In accordance with the provisions of 37 C.F.R. § 1.825(a), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the substitute "Sequence Listing" submitted herewith do not constitute new matter. The amendments included herein add two (2) new SEQ ID NOs for sequences present in the specification at page 37, line 1, now designated SEQ ID NOs: 31 and 32. The undersigned hereby states that the amendments provided herein have support in the application as filed. Also, the amendment to the paper copy of the "Sequence Listing," in accordance with

1.821(a) is accompanied by a substitute copy of the computer readable form including all previously submitted data with the amendment incorporated therein.

Applicants respectfully request entry of this sequence listing and submit that the sequence listing and amendment do not constitute new matter.

**CONCLUSION**


It is believed that no additional fees are required with this submission. However, in the event that additional fees are deemed necessary, to maintain the present application pending, or in the event of any variance between the amount enclosed and the fees determined by the U.S. Patent and Trademark Office, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-0206.**

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: February 9, 2007

By:

  
Robert M. Schulman  
Registration No. 31,196

Christopher J. Nichols, Ph.D.  
Registration No. 55,984

HUNTON & WILLIAMS LLP  
Litigation, Intellectual Property & Antitrust  
1900 K Street, N.W. Suite 1200  
Washington, D.C. 20006  
Telephone (202) 955-1500  
Fax: (202) 778-2201

RMS/CJN:cdh